Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DDMAC Gets Aggressive On Downplaying Risk Info, Sends Three Letters In Three Weeks

This article was originally published in The Pink Sheet Daily

Executive Summary

Materials aimed at patients and professionals targeted in letters to Iroko, Eisai and Shire.

You may also be interested in...



Eisai Draws U.S. FDA Warning Letter For Misleading Efficacy and Safety Claims

WASHINGTON - U.S. FDA issued a warning letter to Eisai for "serious" violations regarding a Dacogen (decitabine) marketing document that minimize risk and "greatly overstates the efficacy of Dacogen.

Inflamed Language: FDA Sends Harsh Warning Letter To Allergan For Acne Drug

Allergan gets slammed for Aczone Gel promotional claims that FDA says are backed by data "not even nominally statistically significant."

FDA Relies On Cognition Research To Spot Misleading Ads – Draft Guidance

FDA is harnessing established science on human cognition to assess whether a device or drug maker's advertisement is misleading, according to a May 27 draft 1guidance document from the agency

Related Content

Topics

UsernamePublicRestriction

Register

PS068799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel